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KCNH2 encodes the Kv11.1 α-subunit that underlies the rapidly activating delayed-
rectifier K+ current in the heart. Loss-of-function KCNH2 mutations cause long
QT syndrome type 2 (LQT2), and most LQT2-linked missense mutations inhibit
the trafficking of Kv11.1 channel protein to the cell surface membrane. Several
trafficking-deficient LQT2 mutations (e.g., G601S) generate Kv11.1 proteins that
are sequestered in a microtubule-dependent quality control (QC) compartment in
the transitional endoplasmic reticulum (ER). We tested the hypothesis that the QC
mechanisms that regulate LQT2-linked Kv11.1 protein trafficking are mutation-specific.
Confocal imaging analyses of HEK293 cells stably expressing the trafficking-deficient
LQT2 mutation F805C showed that, unlike G601S-Kv11.1 protein, F805C-Kv11.1
protein was concentrated in several transitional ER subcompartments. The microtubule
depolymerizing drug nocodazole differentially affected G601S- and F805C-Kv11.1
protein immunostaining. Nocodazole caused G601S-Kv11.1 protein to distribute into
peripheral reticular structures, and it increased the diffuse immunostaining of F805C-
Kv11.1 protein around the transitional ER subcompartments. Proteasome inhibition
also affected the immunostaining of G601S- and F805C-Kv11.1 protein differently.
Incubating cells in MG132 minimally impacted G601S-Kv11.1 immunostaining, but
it dramatically increased the diffuse immunostaining of F805C-Kv11.1 protein in the
transitional ER. Similar results were seen after incubating cells in the proteasome
inhibitor lactacystin. Differences in the cellular distribution of G601S-Kv11.1 and F805C-
Kv11.1 protein persisted in transfected human inducible pluripotent stem cell derived
cardiomyocytes. These are the first data to visually demonstrate mutation-specific
differences in the trafficking-deficient LQT2 phenotype, and this study has identified
a novel way to categorize trafficking-deficient LQT2 mutations based on differences in
intracellular retention.
Keywords: K+ channel, trafficking, long QT syndrome, arrhythmia, Kv11.1, hERG
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INTRODUCTION
Long QT syndrome (LQTS) is a disorder characterized by delayed
ventricular repolarization, prolongation of the QT interval on
an electrocardiogram (ECG), and an increased risk for the
ventricular arrhythmia Torsades de Pointes (Crotti et al., 2008).
LQT2 is a major form of LQTS, which is caused by loss-
of-function (LOF) mutations in the KCNH2 gene (a.k.a the
human ether-a-go-go related gene or hERG) (Curran et al.,
1995; Sanguinetti et al., 1996; Smith et al., 2016). KCNH2
encodes the pore-forming Kv11.1 α-subunits that conduct the
rapidly activating delayed-rectifier K+ current (IKr) in the heart
(Trudeau et al., 1995).
The majority of LQT2-linked mutations are missense, and
heterologous expression studies demonstrate that ∼90% of
LQT2 missense mutations decrease the intracellular transport
(trafficking) of Kv11.1 channels to the cell surface membrane
(Zhou et al., 1998a; Ficker et al., 2000a; Anderson et al., 2006,
2014). Trafficking-deficient LQT2 mutations are postulated to
disrupt Kv11.1 α-subunit protein folding/assembly and cellular
quality control (QC) mechanisms in endoplasmic reticulum (ER)
prevent their trafficking early in the secretory pathway (Zhou
et al., 1998a, 1999; Ficker et al., 2003; Delisle et al., 2005; Gong
et al., 2005; Walker et al., 2007, 2010; Foo et al., 2016). A key
finding is several drugs that bind to Kv11.1 channels and block
IKr (e.g., E-4031) can act as “pharmacological chaperones” to
improve the trafficking and functional expression for many LQT2
channels (pharmacological correction) (Zhou et al., 1999; Ficker
et al., 2002; Anderson et al., 2006, 2014). This is an important
finding because it indicates that some trafficking-deficient LQT2
channels are promising targets for therapeutic intervention to
improve delivery of channels to the surface membrane. Data
suggest that pharmacological chaperones bind to the high affinity
drug-binding site in the Kv11.1 pore to stabilize Kv11.1 channel
conformations suitable for ER export into the secretory pathway
(Zhou et al., 1999; Ficker et al., 2002; Ellgaard and Helenius, 2003;
Delisle et al., 2005; Gong et al., 2006).
We previously studied the cellular QC mechanisms that
prevent the trafficking of the LQT2-linked missense mutations
Gly601Ser (G601S) early in the secretory pathway. In control
conditions, most of the G601S-Kv11.1 protein is excluded from
ER exit sites (ERES) and sequestered in a microtubule-sensitive
ER compartment that contains the transitional ER protein
BAP31 (Furutani et al., 1999; Ficker et al., 2002; Wakana
et al., 2008; Smith et al., 2011, 2013). This transitional ER
compartment did not contain other ER or ER Golgi Intermediate
proteins, including calnexin, proteins with the ER retention
KDEL sequence, the ER-associated degradation (ERAD) protein
derlin-1, the ERES protein Sec31, or the ER-Golgi intermediate
compartment 53 kDa protein (ERGIC-53). Importantly, we
found that incubating cells in the pharmacological chaperone E-
4031 directly increased the trafficking of the sequestered G601S-
Kv11.1 channels to the cell surface membrane (Smith et al.,
2013). In this study we investigate the cellular QC control
mechanisms that prevent the trafficking of the LQT2-linked
missense mutation F805C (Ficker et al., 2002). Unlike G601S
(which is located on the extracellular side of the Kv11.1 α-subunit
in the pore domain), F805C is located on the intracellular portion
of the Kv11.1 α-subunit in the cyclic nucleotide-binding domain
(CNBD) and does not undergo pharmacological correction with
E-4031 because it likely impairs Kv11.1 tetramer assembly (Ficker
et al., 2002; Delisle et al., 2003). We tested the hypothesis that the
ER QC control mechanisms that prevent the trafficking of G601S-
and F805C-Kv11.1 proteins are different.
MATERIALS AND METHODS
Cell Lines and Drug Exposure
The Human Embryonic Kidney 293 (HEK293) cells used
in this study stably express Kv11.1 channel proteins (wild
type or WT, G601S, R752W, or F805C) and they have
been previously described (Zhou et al., 1998b; Delisle et al.,
2003; Anderson et al., 2006). Cells are cultured at 37◦C
(5% CO2) in MEM supplemented with 10% Fetal Bovine
Serum (FBS, Invitrogen, Carlsbad, CA, United States) and
geneticin. The data shown in Figures 1–4, 5B are obtained
from stably expressing cell lines. For some experiments we
transiently transfected G601S- or F805C-Kv11.1 plasmid cDNA
in HEK293 cells. Transfections were performed similar to that
previously described (Anson et al., 2004), 3 µg of Kv11.1
plasmid cDNA was transfected with the Superfect Transfection
Reagent (Qiagen, Germantown, MD, United States). The data
for Figure 5A are from transiently expressing HEK293 cells.
We also used transiently transfected iCell Cardiomyocytes
(Cellular Dynamics International, Madison, WI, United States).
iCell Cardiomyocytes were transiently transfected with green
fluorescent protein (GFP) tagged Kv11.1 cDNA plasmids (3 µg)
using the Viafect (Promega, Madison, WI, United States)
transfection reagent and the protocol for iCell Cardiomyocytes.
The GFP cDNA is located in-frame and upstream of the
Kv11.1 protein start site. For pharmacological studies, we
incubated cells in nocodazole (20 µM) (Millipore, Sigma, St.
Louis, MO, United States), bortezomib, lactacystin, and MG132
(Millipore, Sigma, St. Louis, MO, United States), or E-4031
(10 µM) (Alomone Laboratories, Jerusalem, Israel). Nocodazole,
bortezomib, lactacystin or MG132 were dissolved in DMSO and
added to the MEM (final DMSO concentration was <0.1%).
E-4031 was dissolved in water. Control studies were done in
parallel with equivalent amounts of vehicle (DMSO or water)
only.
Immunocytochemistry and Confocal
Imaging
Immunocytochemistry and confocal imaging experiments
were done similar to those previously described (Smith
et al., 2011, 2013). HEK293 cells or iCell Cardiomyocytes
were plated in 35 mm tissue culture plates containing
collagen-coated coverslips. Cells were fixed with 4% buffered
paraformaldehyde for 10 min, permeabilized with triton X-100
(0.1%) for 10 min, and rinsed in 0.75% glycine buffer for
10 min to quench background fluorescence. The cells were
incubated with 2 mL blocking solution (10% goat serum
in PBS) for 1 h to block non-specific binding sites, and
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FIGURE 1 | F805C selectively co-localizes with BAP31. (A) Representative
confocal images of HEK293 cells expressing F805C-Kv11.1 protein showing
the overlap between anti-Kv11.1 and anti-ER/ERGIC protein immunostaining.
Anti-Kv11.1 immunostaining is shown in red; anti-calnexin (n = 12 images),
anti-Sec31 (n = 19 images), anti-ERGIC-53 (n = 19 images), anti-derlin-1
(n = 18 images), anti-KDEL (n = 15 images), or anti-BAP31 (n = 17 images) is
shown as green; overlapping immunostaining of red and green signals of
similar intensities is shown as yellow; and the cell nuclei are labeled blue. The
arrowheads highlight the distinct immunostaining pattern of F805C-Kv11.1
protein, and the scale bar represents 10 µm. (B) The mean Costes’ Pearson
Coefficient (PC) for the image data sets are shown. PC values at or below the
dashed line are (PC = 0.5) indicative of weak or no co-localization. Two
independent cultures were tested for each condition.
the cells were subsequently incubated with the appropriate
primary antibodies: anti-Kv11.1 (1:1000, Alomone Laboratories,
Jerusalem, Israel), anti-calnexin (1:1000, Abcam, Cambridge,
MA, United States), anti-KDEL (1:1000, Abcam, Cambridge,
MA, United States), anti-Sec31a (1:100, BD Labs, Franklin Lakes,
NJ, United States), anti-Bap31 (1:500, Abcam, Cambridge, MA,
United States), and anti-ERGIC-53 (1:1000, Alexis Biochemicals,
Plymouth Meeting, PA, United States) mixed with blocking
solution at room temperature. Excess antibody was washed
off with three 10 min long rinses of blocking solution. The
cells were then incubated for 1 h with the appropriate Highly
Cross-absorbed Alexa Fluor antibodies (1:500, Invitrogen Inc.,
Carlsbad, CA, United States). The cells were washed four
times for 10 min with blocking solution alone. After the final
wash, the coverslips were mounted onto a slide using ProLong
Gold with DAPI mounting medium (Invitrogen, Carlsbad,
CA, United States). For iCell Cardiomyocytes experiments, we
prepared the cells as described above but utilized the fluorescence
signal from GFP for imaging analyses. Imaging was performed
at the University of Kentucky Imaging Facility using a Leica TSP
SP5 confocal microscope (Leica, Wetzler, Germany). HEK293
cells or iCell Cardiomyocytes did not show any labeling with any
of the secondary antibodies when used alone (data not shown).
Data are shown as representative single z-scan images for each
fluorescence signal (fluorescent images). Overlapping signals of
similar intensities colored as red and green are shown as yellow
and green and purple are shown as white.
Co-localization analyses were performed using ImageJ1. We
calculated the Pearson Coefficient (PC) and the Manders
Colocalization Coefficients (MCC) for some experiments. The
PC is the goodness of fit for the linear regression describing the
relation between overlapping signal intensities. We calculated the
coefficients using the intensity thresholds defined by the Costes’
approach to minimize the contribution of noise. Using the Costes
PC approach, the values range between 0 (no co-localization)
to 1 (100% co-localization). Weak co-localization is defined as
having PC values < 0.5 (Bolte and Cordelieres, 2006). The MCC
calculates the fraction of overlap between the signals even if the
intensities of the signals are very different from one another.
The MCC also vary from 0 (no overlap) to 1 (complete overlap)
and are calculated for both signals (M1 and M2). We use the
MCC to describe the fraction of Kv11.1 signal in compartments
containing the BAP31 signal (M1), or to describe the fraction of
BAP31 signal in compartments containing Kv11.1 signal (M2).
Statistics
A one-way ANOVA was performed on data sets. In order
to identify which experimental groups differed from control,
post hoc Bonferroni’s tests on selected data sets were performed
(Prism, La Jolla, CA, United States). Significance was reported at
p< 0.05.
RESULTS
F805C-Kv11.1 Protein Selectivity
Co-localizes With BAP31
We initially tested whether the trafficking-deficient F805C-
Kv11.1 protein co-localized with different ER/ERGIC
proteins (Figure 1A) in HEK293 cells by calculating the
Costes PC. Confocal data showed that F805C-Kv11.1 protein
immunostaining localized into several discrete compartments
throughout the cell. Based on the PC analysis, the F805C-Kv11.1
protein did not (or only weakly) co-localize with the ER lectin
chaperone calnexin (Hammond et al., 1994), the ER Golgi
Intermediate Complex (ERGIC) protein ERGIC-53 (Schweizer
et al., 1993), the ERES protein Sec31 (Salama et al., 1997), the
ERAD protein derlin-1 (Lilley and Ploegh, 2004), or ER proteins
that contain the KDEL ER retention signal sequence (Munro
and Pelham, 1987) (Figure 1B). However, F805C-Kv11.1 protein
co-localized with the transitional ER protein BAP31. These
data suggest that F805C-Kv11.1 protein is concentrated in the
transitional ER.
1https://imagej.nih.gov
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FIGURE 2 | G601S- and F805C-Kv11.1 proteins show distinct immunostaining patterns. Shown are representative confocal images of HEK293 cells expressing
(A) G601S- or (B) F805C-Kv11.1 protein immunostained with anti-Kv11.1 (red, first column), anti-Bap31 (green, second column) in control conditions (top row;
n = 13 images for G601S and n = 17 images for F805C) or after incubation in nocodazole (bottom row; n = 15 images for G601S and n = 16 images for F805C). The
overlay images are also shown (overlapping immunostaining is yellow, third column), and the white dashed box portion of the overlay image is shown in larger detail
(fourth column). The nuclei are labeled blue. The arrowheads in (A) highlight the reticular immunostaining pattern of G601S-Kv11.1 protein after nocodazole
treatment, the arrowheads in (B) highlight the unique immunostaining pattern of F805C-Kv11.1 protein, and the scale bar represents 10 µm. Two independent
cultures were tested for each condition.
G601S- and F805C-Kv11.1 Proteins Show
Differences in Protein Immunostaining
We previously showed that G601S-Kv11.1 protein is sequestered
in microtubule-dependent ER QC compartment with BAP31
(Smith et al., 2011, 2013). We directly compared the anti-
Kv11.1 protein immunostaining pattern of HEK293 cells
expressing G601S-Kv11.1 or F805C-Kv11.1 protein in control
conditions or after treatment in the microtubule depolymerizing
agent nocodazole (20 µM) for 2 h. Similar to what was
previously reported, cells expressing G601S-Kv11.1 protein
showed a peri-nuclear immunostaining pattern that diffused
into the cell periphery and co-localized with BAP31 in
control conditions (Figure 2A; PC = 0.62 ± 0.02 in control
n = 13 images) (Smith et al., 2011, 2013). Incubating
cells in nocodazole caused G601S-Kv11.1 and BAP31 protein
to redistribute together into several peripheral reticulated
membrane compartments (PC = 0.72 ± 0.02 after nocodazole,
n = 15 images). In control conditions, the F805C-Kv11.1 protein
immunostaining pattern was qualitatively different than the
G601S-Kv11.1 protein immunostaining pattern (Figure 2B).
Similar to Figure 1A, the F805C-Kv11.1 protein immunostaining
was concentrated in several compartments that co-localized
with BAP31 protein (PC = 0.71 ± 0.01 in control n = 17
images). Nocodazole treatment did not cause F805C-Kv11.1
protein to redistribute to reticulated membrane compartments,
but it modestly increased the amount of diffuse F805C-
Kv11.1 protein immunostaining, still co-localizing with BAP31
(PC = 0.77 ± 0.02 after nocodazole, n = 16 images). We
conclude that unlike G601S-Kv11.1 protein, F805C-Kv11.1
protein likely concentrates to distinct sub-compartments in the
transitional ER.
F805C-Kv11.1 Protein Immunostaining Is
Disrupted by Proteasome Inhibition
The WT Kv11.1 α-subunit is synthesized in the ER as a ∼135
kDa N-linked glycoprotein, and once the WT-Kv11.1 α-subunit
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FIGURE 3 | F805C-Kv11.1 protein immunostaining is sensitive to proteasome inhibition. Shown are representative images of HEK293 cells expressing (A) G601S-
or (B) F805C-Kv11.1 protein immunostained with anti-Kv11.1 (red, first column), anti-Bap31 (green, second column), the overlay (co-localization is shown as yellow,
third column), and the white dashed box portion of the overlay in more detail (fourth column). The nuclei are shown in blue and the scale bars represent 10 µm. The
top row of images in (A,B) show control conditions (n = 13 images for G601S and n = 17 images for F805C) and the second row of images in (A,B) show cells after
incubation in 5 µM MG132 for 5 h (n = 15 images for G601S and n = 17 images for F805C). The arrowheads in (B) highlight the immunostaining pattern of
F805C-Kv11.1 protein in control conditions. The bottom row of images show F805C-Kv11.1 protein immunostaining after incubation in 5 µM lactacystin (n = 17
images) for 5 h. Two independent cultures were tested for each condition.
traffics to the Golgi apparatus, it is terminally glycosylated
to a ∼155 kDa glycoprotein (Zhou et al., 1998b; Petrecca
et al., 1999). Studies show that only 60% of the 135 kDa
WT-Kv11.1 protein is processed to the terminally glycosylated
155 kDa form. The fraction of WT-Kv11.1 protein that fails
to mature is degraded via the ERAD (ubiquitin-proteasome)
pathway (Gong et al., 2005). In the presence of proteasome
inhibitors, there is an increase in the immature form of WT-
Kv11.1 protein, and a decrease in the efficiency in the ER
dislocation of WT-Kv11.1 protein in ERAD pathway (Gong
et al., 2005). Therefore, we tested whether the proteasome
inhibitor MG132 impacted G601S- or F805C-Kv11.1 protein
immunostaining. We incubated HEK293 cells expressing G601S-
or F805C-Kv11.1 protein in the proteasome inhibitor MG132
(5 µM) for 5 h (Figures 3A,B). This incubation time is
based on previous reports that investigated the impact that
proteasome inhibitors had on the ER retention of proteins
in other studies (Kamhi-Nesher et al., 2001; Spiliotis et al.,
2002; Wakana et al., 2008). Compared to control cells,
incubating cells in MG132 did not appear to alter G601S-
Kv11.1 protein immunostaining or its co-localization with BAP31
(PC = 0.57 ± 0.02 after MG132, n = 15 images). In contrast,
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FIGURE 4 | Proteasome inhibition increases the fraction of Kv11.1 signal overlapping with BAP31 signal. (A) Shown are representative confocal images of HEK293
cells expressing WT-Kv11.1 protein immunostained with anti-Kv11.1 (red, first column), anti-Bap31 (green, second column) in control conditions. The nuclei are
labeled blue, and the scale bar represents 10 µm. (B) Shown is the graph for the MCC that describes the fraction of Kv11.1 signal in compartments containing the
BAP31 signal (M1, left graph), as well as the fraction of BAP31 signal in compartments containing Kv11.1 signal (M2, right graph). We compared M1 and M2 for cells
stably expressing WT-, G601S-, or F805C-Kv11.1 protein in control conditions (n = 19, 13, and 17 images, respectively, ∗p < 0.05 compared to cells expressing
WT-Kv11.1 in control conditions). We also compared the M1 or M2 in cells expressing F805C-Kv11.1 in control conditions to cells incubated in nocodazole (F805C
noc, n = 16 images), MG132 (F805C MG132, n = 17 images), or lactacystin (F805C lact, n = 17 images). At least two independent cultures were tested for each
condition (#p < 0.05) compared to cells expressing F805C-Kv11.1 protein in control conditions. (C) Shown are representative images of cells expressing
F805C-Kv11.1 protein immunostained with anti-Kv11.1 (red) in control conditions or in different concentrations of bortezomib for 5 h. The nuclei are labeled blue.
The effect of bortezomib on F805C-Kv11.1 immunostaining was confirmed in two independent test cultures (n = 5–11 images per condition).
treating cells expressing F805C-Kv11.1 protein dramatically
transformed the protein immunostaining pattern from several
compartments to a peri-nuclear pattern that diffused into
the cell periphery (Figure 3B). Although incubating cells in
MG132 dramatically altered the distribution of F805C-Kv11.1
protein, the F805C-Kv11.1 protein still co-localized with BAP31
(PC = 0.78 ± 0.02 after MG132, n = 17 images). We next
determined if another proteasome inhibitor similarly affected
the immunostaining pattern of cells expressing F805C-Kv11.1
protein. Incubating cells expressing F805C-Kv11.1 protein in
the proteasome inhibitor lactacystin for 5 h also altered the
F805C-Kv11.1 protein immunostaining pattern similar to cells
incubated with MG132 (Figure 3B). Moreover, incubating cells
in lactacystin did not alter F805C-Kv11.1 protein co-localization
with BAP31 (PC = 0.72 ± 0.03 after lactacystin, n = 17 images).
These data indicate that F805C-Kv11.1 protein concentrates in
sub-compartments of the transitional ER that are sensitive to
proteasome inhibition.
Nocodazole, Lactacystin, and MG132
Increase the Fractional Overlap of
F805C-Kv11.1 Protein With BAP31 and
Immunostaining
The Costes’ PC quantifies the co-localization between Kv11.1 and
BAP31 protein immunostaining by measuring the goodness of
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FIGURE 5 | Transient transfection of G601S- or F805C-Kv11.1 does not alter
mutation-specific differences in immunostaining pattern, and cells stably
expressing R752W-Kv11.1 protein show similar immunostaining patterns as
cells expressing F805C-Kv11.1 protein. (A) Representative confocal images of
HEK293 cells transiently expressing G601S-Kv11.1 (left) or F805C-Kv11.1
(right) protein showing the overlapped anti-Kv11.1 (red) and anti-BAP31
immunostaining (green) (n = 12 images for each, from 2 independent cultures).
Overlapping immunostaining of red and green signal of similar intensities is
shown as yellow and the cell nuclei are labeled blue. The transfection
efficiency is <100%, so not all cells were expressing Kv11.1 protein.
(B) Representative confocal images of HEK293 cells stably expressing
R752W-Kv11.1 protein showing the overlap between anti-Kv11.1 (red) and
anti-BAP31 immunostaining (green). Overlapping immunostaining of red and
green signal of similar intensities is shown as yellow and the cell nuclei are
labeled blue. The arrowheads highlight the immunostaining pattern of
R752W-Kv11.1 protein, and the scale bar represents 10 µm. The mean
Costes’ Pearson Coefficient (PC) for the image data is 0.65 ± 0.01 (n = 11
images from 2 independent cultures).
fit for the relation between overlapping signal intensities. An
additional approach for confocal image analysis is to calculate
the MCC, which provides a measure of how much one signal
overlaps with a second signal. Qualitatively, the major effect of
incubating cells expressing F805C-Kv11.1 protein in nocodazole
(Figure 2B), MG132, or lactacystin (Figure 3B) was to increase
the overlap of Kv11.1 protein with BAP31 immunostaining,
therefore we quantified the MCC between Kv11.1 protein and
BAP31.
Manders Colocalization Coefficients analyses have not been
done for cells expressing Kv11.1 proteins. Therefore we imaged
cells stably expressing WT-Kv11.1 protein (Figure 4A) and
compared the M1 and M2 with cells expressing G601S-
or F805C-Kv11.1 protein. The data show the M1 for cells
expressing WT-Kv11.1 protein is smaller than that of cells
expressing G601S-Kv11.1 protein (Figure 4B). In other words,
cells expressing WT-Kv11.1 protein show less overlap of Kv11.1
protein with BAP31 compared to cells expressing G601S-
Kv11.1 protein. These data are consistent with more G601S-
Kv11.1 protein retained in the transitional ER compartment.
In contrast, the M1 for cells expressing WT-Kv11.1 protein
is greater than F805C-Kv11.1 protein. This is because F805C-
Kv11.1 protein concentrates in several small transitional
ER subcompartments. We conclude that mutation-specific
differences in the trafficking-deficient LQT2 phenotype can
be quantified by differences in the fraction of Kv11.1 protein
overlapping with BAP31.
In contrast the M2 for cells expressing WT-Kv11.1 protein is
smaller than cells expressing G601S- or F805C-Kv11.1 protein
(Figure 4B). This means that more BAP31 overlapped with
Kv11.1 protein in cells expressing G601S- or F805C-Kv11.1
protein. This is because cells expressing WT-Kv11.1 protein
appear to have more Kv11.1 protein in the cell surface membrane
(Figure 4A).
We next determined how incubating cells expressing
F805C-Kv11.1 protein in nocodazole or the proteasome
inhibitors affected the M1 and M2 (Figure 4B). Compared
to control cells expressing F805C-Kv11.1, incubating cells
expressing F805C-Kv11.1 protein in the proteasome inhibitors
increased M1. These data demonstrate that nocodazole and
the proteasome inhibition increased the amount of F805C-
Kv11.1 protein in the larger transitional ER compartment.
We did not see any significant changes in M2, indicating that
incubating cells in nocodazole or proteasome inhibitors did
affect the high amount of BAP31 overlap with F805C-Kv11.1
protein.
The effect of proteasome inhibitors on the immunostaining
patterns of F805C-Kv11.1 protein was striking. Inhibiting the
proteasome pathway is an approach in the treatment of
certain cancers, including myeloma and mantle cell lymphoma
(Chen et al., 2011). Bortezomib is the first FDA approved
proteasome inhibitor to be implemented in cancer treatment.
Therefore, we also determined the impact that different
concentrations of bortezomib had on the immunostaining
pattern of F805C-Kv11.1 protein (Figure 4C). We found that,
similar to MG132 and lactacystin, incubating cells in different
concentrations of bortezomib for 5 h transformed the F805C-
Kv11.1 protein immunostaining pattern to a diffuse peri-nuclear
pattern.
G601S- and F805C-Kv11.1 Proteins Show
Differences in Protein Immunostaining in
Transiently Transfected Cells
One possible reason for the immunostaining difference between
the cell lines expressing G601S- and F805C-Kv11.1 could
be due to differences in protein expression. The unique
immunostaining pattern of F805C-Kv11.1 protein might
be because the mutant protein levels are too high for a
normal functioning of the cellular QC system. Therefore
we immunostained HEK293 cells transiently transfected
with equal amounts of G601S- or F805C-Kv11.1 plasmid
DNA. Importantly, the mutation-specific immunostaining
pattern of G601S- and F805C-Kv11.1 proteins were similar
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to what was seen in stably expressing cells (Figure 5A).
These data suggest that the mutation-specific difference in
immunostaining was not due to differences in mutant Kv11.1
cDNA levels.
We previously showed that cells stably expressing different
LQT2-linked mutations in the Kv11.1 pore region (A614V- or
N629D-Kv11.1) exhibit a diffuse immunostaining pattern that
co-localizes with BAP31 similar to G601S-Kv11.1 protein
(Smith et al., 2013). We determined whether R752W-
Kv11.1 (another LQT2-linked mutation that is located
intracellular CNBD, impairs Kv11.1 tetramer assembly,
and does not undergo pharmacological correction with
E-4031) exhibited a similar immunostaining pattern as cells
expressing F805C-Kv11.1 protein. Imaging cells stably expressing
R752W-Kv11.1 protein showed that it also concentrated in
transitional ER subcompartments (Figure 5B). Together,
the data demonstrate that the immunostaining pattern seen
in cells expressing of F805C-Kv11.1 protein is also seen in
cells expressing other LQT2-linked mutant proteins in the
CNBD.
G601S and F805C Show Distinct
Immunostaining Patterns in iPSC-CMs
We next determined whether the mutation-specific
immunostaining patterns of G601S- or F805C-Kv11.1 proteins
persisted in human inducible pluripotent stem cell derived
cardiomyocytes (iPSC-CMs). This will help to determine if
mutation-specific differences occurs in a more native-like cell
that expresses endogenous WT-Kv11.1 protein (including the
shorter Kv11.1b subunit) (Jones et al., 2004, 2014). iPSC-CMs
were transfected with WT-, G601S- or F805C-Kv11.1 proteins
tagged with GFP on the Kv11.1 amino-terminus to distinguish
between heterologously expressed and endogenous WT-Kv11.1
or WT-Kv11.1b protein. We immunostained the cells for
BAP31. Similar to what we previously showed in HEK293
cells, WT-Kv11.1-GFP protein expressed in iPSC-CMs did not
co-localize with BAP31 (Figures 6A,D) (Smith et al., 2013).
G601S-Kv11.1-GFP expressed in iPSC-CMs co-localized with
BAP31, and importantly, this co-localization was decreased in
iPSC-CMs treated with the pharmacological chaperone E-4031
for 24–48 h (Figures 6B,D). In most iPSC-CMs, F805C-Kv11.1-
GFP protein concentrated in discrete compartments (although
the co-localization with BAP31 was not as strong as it was in
HEK293 cells) (Figures 6C,D). These data confirm that the
differences in subcellular localization of WT-, G601S-, and
F805C-Kv11.1 proteins persisted in a cell model of human
cardiomyocytes.
DISCUSSION
In this study we demonstrate that the trafficking-deficient
LQT2 missense mutation F805C generated Kv11.1 protein
that accumulates in discrete ER subcompartments. In HEK293
cells F805C-Kv11.1 protein did not co-localize with several
ER/ERGIC marker proteins, but it did co-localize with the
transitional ER protein BAP31. The immunostaining pattern
of F805C-Kv11.1 protein was sensitive to the microtubule
depolymerizing drug nocodazole, as well as the proteasome
inhibitors MG132 or lactacystin. Interestingly, these drugs did
not alter F805C-Kv11.1 protein co-localization with BAP31, but
they all caused the F805C-Kv11.1 protein to become more diffuse
and increased the overlapping immunostaining between F805C-
Kv11.1 and BAP31. In contrast, G601S-Kv11.1 protein did not
accumulate in distinct subcompartments and its immunostaining
pattern was insensitive to proteasome inhibition. Importantly,
the mutation-specific differences in the subcellular patterns
of G601S- and Kv11.1-Kv11.1 protein were also present in
human iPSC-CMs. We conclude that distinct QC mechanisms
in the ER regulate the retention of G601S- and F805C-Kv11.1
protein.
Mutation-specific differences in trafficking-deficient
phenotype for LQT2 mutations have long been recognized
(Ficker et al., 2000b; Anderson et al., 2006, 2014; Smith et al.,
2016). For example, there are mutation-specific differences
in pharmacological correction, intragenic suppression,
and dominant negative effects on the trafficking of WT-
Kv11.1 protein, suggesting that different mutations likely
disrupt different steps in the native Kv11.1 protein folding
pathway (e.g., co-assembly of α-subunits, formation of the
voltage-sensor/pore domains, increasing the proximity of
the NH2 and COOH termini, etc.) (Ficker et al., 2000a;
Delisle et al., 2005; Anderson et al., 2006; Smith et al., 2016).
However, this is the first study to investigate mutation specific
differences in cellular mechanisms associated with ER retention.
Although we focus only on two different mutations, we
found that other trafficking-deficient LQT2-linked proteins
have immunostaining/co-localization patterns similar to cells
expressing G601S-Kv11.1 (A614V and N629D) (Smith et al.,
2013) or F805C-Kv11.1 protein (R752W, Figure 5B). Therefore,
this study has identified a novel way to categorize subgroups
of trafficking-deficient LQT2 mutations. We expect these
findings will help identify new drugs that improve LQT2
protein trafficking by targeting mutation-specific ER QC
mechanisms.
The exact mechanism by which proteasome inhibitors
alter F805C-Kv11.1 protein immunostaining remains unclear.
Previous studies show that retrotranslocation of misfolded
proteins into the cytosol likely occurs concurrently with their
degradation by the proteasome, and that upon inhibition of
proteasomal activity, misfolded proteins remain intact in the
secretory pathway (Hirsch and Ploegh, 2000). Consistent with
this concept, studies show that inhibition of the proteasome
decreases the efficiency of WT-Kv11.1 protein dislocation from
the ER (Gong et al., 2005). However, F805C-Kv11.1 protein did
not co-localize with the ERAD protein derlin-1, and surprisingly,
we found that longer-term proteasome inhibition did not
improve Kv11.1 protein trafficking but actually appeared to
inhibit it (data not shown).
An intriguing implication to the findings in this study is
that, because different immunostaining patterns of different
LQT2-linked mutant proteins can be easily visualized
with microtubule depolymerizing agents or proteasome
inhibitors, cell lines expressing these trafficking-deficient Kv11.1
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FIGURE 6 | G601S- and F805C-Kv11.1 proteins show distinct immunostaining patterns in iPSC-CMs. Shown are representative images of iPSC-CMs expressing
(A) WT-Kv11.1-GFP, (B) G601S-Kv11.1-GFP, or (C) F805C-Kv11.1-GFP (green, first column), immunostained with anti-BAP31 (purple, second column). Also shown
are the overlays (co-localization is shown as white, third column) and the white dashed box portion of the overlay in more detail (fourth column). The nuclei are
stained in blue and the scale bar represents 10 µm. The row in (A), top row in (B), and row in (C) show iPSC-CMs in control conditions. The arrowheads in (C)
highlight the unique fluorescence pattern of cells expressing F805C-Kv11.1-GFP. The bottom row in (B) shows images from iPSC-CMs expressing
G601S-Kv11.1-GFP after incubation in 10 µM E-4031 (E4) for ∼24 h. (D) The mean Costes’ Pearson Coefficient (PC) for the iPSC-CMs expressing WT-GFP (n = 16
images), G601S-GFP (n = 20 images), G601S-GFP after incubation in 10 µM E-4031 (n = 19 images), or F805C-GFP (n = 14 images) (∗p < 0.05 compared to WT,
#p < 0.05 compared to G601S con). Two independent cultures were tested for each condition.
proteins might be used as a novel drug-screening platform to
identify new anti-neoplastic agents that have microtubule
depolymerization properties or inhibit the proteasome
activity.
There are several limitations to this study. We primarily
used HEK293 cells for most of the experiments in the study,
however, we confirmed similar mutation-specific differences in
the subcellular localization of G601S- and F805C-Kv11.1 proteins
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in iPSC-CMs. Interestingly the co-localization of F805C-Kv11.1
and BAP31 protein was decreased in iPSC-CM. We suspect that
this difference might be due to cell type specific differences. For
example, the subcellular localization of mutant F805C-Kv11.1
protein may be altered by endogenous WT-Kv11.1 proteins
(including the Kv11.1b protein). However, F805C-Kv11.1 is not
expected to co-assemble with other Kv11.1 subunits (Ficker
et al., 2002). Another possibility is that the larger size of iPSC-
CMs might help to better resolve the spatial differences between
F805C-Kv11.1 protein and BAP31. Regardless, the data clearly
show that both G601S- and F805C-Kv11.1 proteins have unique
localization patterns in both cell types, suggesting they are
regulated by different QC pathway interactions.
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